Frontiers in Cardiovascular Drug Discovery. Volume 5

Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Atta-ur-Rahman, Choudhary, M. Iqbal
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Singapore : Bentham Science Publishers, 2020.
Colección:Frontiers in Cardiovascular Drug Discovery Ser.
Temas:
Cardiovascular agents.
Cardiovascular Agents
Agents cardiovasculaires.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Cover
  • Title
  • Copyright
  • End User License Agreement
  • Contents
  • Preface
  • List of Contributors
  • The Lipid Hypothesis: From Resins to Proprotein Convertase Subtilisin/Kexin Type-9 Inhibitors
  • Sudarshan Ramachandran1,2,3, Mithun Bhartia4,5 and Carola S. König3
  • INTRODUCTION
  • CHOLESTEROL
  • Early Evolution of the Relationship between Cholesterol and Atherogenesis
  • LONGITUDINAL PROSPECTIVE OBSERVATIONAL STUDIES AND CVD RISK ALGORITHMS
  • INTERVENTIONAL STUDIES WITH CLINICAL EVENTS AS OUTCOMES
  • Randomised Controlled Bile Sequestrants Trials
  • Randomised Controlled Statin Trials
  • Randomised Controlled Ezetimibe Trials
  • Randomised Controlled PCSK9 Inhibitor Trials
  • THE RECENT CASE AGAINST THE LIPID HYPOTHESIS
  • ROLE OF OTHER LIPID LOWERING AGENTS
  • ROLE OF ANTI-INFLAMMATORY THERAPY
  • REFINING THE LIPID HYPOTHESIS: IDENTIFICATION OF SUBGROUPS DEMONSTRATING EVEN GREATER BENEFIT
  • CONCLUSION
  • DISCLOSURE STATEMENT
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCES
  • The Role of SGLT2i in the Prevention and Treatment of Heart Failure
  • Hasan AlTurki1, Ahmed AlTurki2, Mark Sherman3, Abhinav Sharma2 and Thao Huynh2,*
  • INTRODUCTION
  • HEART FAILURE
  • MECHANISMS OF ACTION OF SGLT2 AND SGTL2I
  • Glucose Homeostasis
  • Cardiovascular Effects of SGLT2i
  • Nephroprotective Effects of SGLT2I
  • CV OUTCOMES IN PATIENTS WITH T2DM
  • RENAL OUTCOMES IN PATIENTS WITH T2DM AND CHRONIC KIDNEY DISEASE (CKD)
  • HEART FAILURE
  • PERIPHERAL ARTERIAL DISEASE
  • ACUTE HEART FAILURE
  • REAL-WORLD DATA
  • CURRENT SGLT2I USES
  • CURRENT USE OF SGLT2 INHIBITORS IN CLINICAL PRACTICE
  • PRACTICAL CONSIDERATIONS WITH SGLT2I PRESCRIPTION
  • FUTURE DIRECTIONS AND ONGOING TRIALS
  • CONCLUSIONS
  • CONSENT FOR PUBLICATION
  • CONFLICTS OF INTEREST
  • ACKNOWLEDEGEMENTS
  • REFERENCES
  • Natural Products and Semi-Synthetic Compounds as Antithrombotics: A Review of the Last Ten Years (2009-2019)
  • Angelo Piato1,* and Cedric Stephan Graebin2,*
  • INTRODUCTION
  • NATURAL PRODUCTS WITH ANTITHROMBOTIC ACTIVITY
  • Antithrombotic Molecules Obtained from Marine-based Sources
  • Antithrombotics from microorganisms
  • Antithrombotics from Plant-based Sources
  • Semi-synthetic compounds with antithrombotic activity
  • CONCLUSION
  • ABBREVIATIONS
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENT
  • REFERENCES
  • Transient Receptor Potential Channels: Therapeutic Targets for Cardiometabolic Diseases?
  • Leidyanne Ferreira Gonçalves, Thereza Cristina Lonzetti Bargut and Caroline Fernandes-Santos*
  • INTRODUCTION
  • TRP CHANNELS
  • TRPA (ankyrin) Family
  • TRPC (canonical) Family
  • TRPM (melastatin) Family
  • TRPML (mucolipin) Family
  • TRPP (polycystin) Family
  • TRPV (vanilloid) Family
  • TRP CHANNELS AND CARDIOVASCULAR DISEASES
  • TRP Expression
  • TRPA1
  • TRPC
  • TRPM
  • TRPV

Ejemplares similares